Curocell (XKRX:372320) EV-to-EBIT : (As of May. 16, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Curocell EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Curocell's Enterprise Value is ₩429,801.67 Mil. Curocell does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Jun. 2023. Therefore, GuruFocus does not calculate Curocell's EV-to-EBIT at this moment.

The historical rank and industry rank for Curocell's EV-to-EBIT or its related term are showing as below:

XKRX:372320' s EV-to-EBIT Range Over the Past 10 Years
Min: -69.21 Med: 0 Max: 0
Current: -15.78

XKRX:372320's EV-to-EBIT is ranked worse than
100% of 427 companies
in the Biotechnology industry
Industry Median: 10.05 vs XKRX:372320: -15.78

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Curocell's Enterprise Value for the quarter that ended in Jun. 2023 was ₩0.00 Mil. Curocell does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Jun. 2023. Therefore, GuruFocus does not calculate Curocell's Earnings Yield (Joel Greenblatt) % at this moment.

Curocell EV-to-EBIT Historical Data

The historical data trend for Curocell's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curocell EV-to-EBIT Chart

Curocell Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-17.93

Curocell Semi-Annual Data
	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	-	-	-	-17.93

Competitive Comparison of Curocell's EV-to-EBIT

For the Biotechnology subindustry, Curocell's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curocell's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curocell's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Curocell's EV-to-EBIT falls into.

Curocell EV-to-EBIT Calculation

Curocell's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	429801.673	/
	=

Curocell (XKRX:372320) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Curocell's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 )	=	EBIT	/	Enterprise Value (Q: Jun. 2023 )
	=		/	0
	=	%

Curocell EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Curocell's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Curocell (XKRX:372320) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curocell Inc (XKRX:372320) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

11, Gukjegwahak 16-ro, Yuseong-gu, Daejeon, KOR, 34002

Website

https://www.curocellbtx.com

Curocell Inc is engaged in medical and pharmaceutical research and development. The company is into development of CAR-T treatments that enhance the natural function of immune cells to eliminate cancer cells through genetic manipulation of human immune cells.

Curocell (XKRX:372320) Headlines

No Headlines